Peroral aromatic retinoid treatment of palmoplantar pustulosis: double-blind comparison of Ro 10-9359 and placebo
DOI:
https://doi.org/10.2340/0001555559271273Abstract
Nineteen patients with chronic, recalcitrant palmoplantar pustulosis took either placebo or aromatic retinoid ethyl ester (Ro 10-9359) during a 4-month therapeutic trial. The maximal dose of Ro 10-9359 varied between 25 and 100 mg per day, according to the individual patient's tolerance. An excellent or good therapeutic response was obtained in 6 out of 9 patients on the active medication and in 2 out of 10 patients on placebo. The difference in therapeutic response between the Ro 10-9359 group and the placebo group was statistically significant (p less than 0.05). Drying and chapping of the lips was the most common side effect of Ro 10-9359 treatment.Downloads
Download data is not yet available.
Downloads
Published
1979-05-01
How to Cite
Jansén, C., Hollmén, A., & Pajarre, R. (1979). Peroral aromatic retinoid treatment of palmoplantar pustulosis: double-blind comparison of Ro 10-9359 and placebo. Acta Dermato-Venereologica, 59(3), 271–273. https://doi.org/10.2340/0001555559271273
Issue
Section
Articles
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
